<DOC>
	<DOCNO>NCT00083096</DOCNO>
	<brief_summary>RATIONALE : Lonafarnib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , temozolomide , work different way stop tumor cell divide stop grow die . Giving lonafarnib together temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lonafarnib give together temozolomide treat patient recurrent primary supratentorial glioma .</brief_summary>
	<brief_title>Lonafarnib Temozolomide Treating Patients With Recurrent Primary Supratentorial Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity lonafarnib administer temozolomide patient recurrent primary supratentorial glioma . - Determine safety tolerability regimen patient . Secondary - Determine mechanism action lonafarnib patient . - Determine pharmacodynamics pharmacokinetics regimen patient . - Determine activity regimen patient . - Determine response regimen patient measurable disease . OUTLINE : This nonrandomized , multicenter , open-label , dose-escalation study lonafarnib . Patients receive oral temozolomide daily day 2-6 course 1 day 1-5 subsequent course . Patients also receive oral lonafarnib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos lonafarnib maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . An additional 3 patient may treat high dose level achieve . Patients follow every 8 week 6 month every 3 month thereafter . PROJECTED ACCRUAL : A total 3-30 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary supratentorial glioma Multifocal disease allow Recurrent disease prior surgery and/or radiotherapy Radiological evidence increase and/or enhance target lesion Amenable temozolomide therapy PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 OR WHO 02 Life expectancy Not specify Hematopoietic Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Hepatic Alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) Transaminases &lt; 2.5 time ULN Bilirubin &lt; 1.5 time ULN Renal Creatinine &lt; 1.7 mg/dL Cardiovascular Cardiac function clinically normal Normal 12lead ECG QTc ≤ 440 msec ECG No ischemic heart disease within past 6 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No unstable systemic disease No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study compliance followup No active recurrent malignancy within past 5 year except cone biopsied carcinoma cervix adequately treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent anticancer biologic agent Chemotherapy At least 4 week since prior chemotherapy ( 6 week temozolomide ) Prior adjuvant chemotherapy allow No 1 prior chemotherapy regimen recurrent disease No concurrent chemotherapy Endocrine therapy Concurrent corticosteroid allow provided treatment remain stable decrease dose least 2 week Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics At least 3 month since prior surgery primary brain tumor Other Concurrent anticonvulsant allow No concurrent anticancer agents No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>